Cerus Corporation (CERS)

In November 2025, Cerus announced record results for Q3 2025 and raised its full-year 2025 product revenue guidance. In January 2026, the company reported preliminary fourth-quarter and full-year 2025 product revenue, with full-year product revenue reaching $206.1 million, a 14% increase over 2024. Cerus shares experienced a 27% gain in January 2026, contributing to a 42% annual gain. In March 2026, Cerus released its Q4 and full-year 2025 financial results, showing solid revenue growth but a slight miss on analyst expectations. Also in March 2026, Cerus received European regulatory approval for its INT200 device and plans to submit a premarket approval application for it in the US by mid-2026. Cathie Wood's ARK Investment Management LLC purchased 612,000 shares of Cerus in March 2026. Vivek Jayaraman was announced as the new CEO of Cerus in March 2026. In April 2026, the share price was $1.86. Insider sentiment for Cerus Corporation has been negative, primarily due to significant open-market selling by key executives.

There is no explicit information indicating significant demand seasonality for Cerus Corp.'s products and services in the provided search results. The company's focus on blood transfusion safety suggests a relatively consistent demand driven by ongoing healthcare needs rather than seasonal fluctuations.

Cerus Corp. develops and commercializes the INTERCEPT Blood System, a technology designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The system utilizes UV-A light to inactivate a broad range of pathogens, including viruses, bacteria, and parasites, while preserving the therapeutic properties of blood products. The company's major products include INTERCEPT Blood System for platelets and plasma, designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion. The INTERCEPT Fibrinogen Complex (IFC), produced using the plasma system, is a pathogen-reduced cryoprecipitated fibrinogen complex used for treating and controlling bleeding, particularly in cases of massive hemorrhage associated with fibrinogen deficiency. The INTERCEPT Blood System for red blood cells is currently in late-stage clinical development to inactivate pathogens in red blood cells. The INTERCEPT Illuminator is an LED-based device used for treating blood components.

Cerus Corp. has a global presence, selling its INTERCEPT platelet and plasma systems through direct sales forces and distributors in the United States, Europe, the Commonwealth of Independent States countries, the Middle East, Latin America, and other international regions. The company's products are used in approximately 40 countries worldwide.

Cerus Corp.'s brand reputation appears to be positive, largely driven by its core mission and achievements. The company is recognized for safeguarding the world's blood supply and improving the safety and availability of transfused blood components. In 2025, Cerus achieved record annual product sales and its highest annual kit shipments. Recent positive developments, such as European regulatory approval for its INT200 device and a group purchasing agreement with Blood Centers of America in the US, further contribute to a favorable brand image.

Cerus Corp. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock, with figures ranging from approximately 68.17% to 76.34% across different reports. Major institutional shareholders include BlackRock, Inc., ARK Investment Management LLC, and Vanguard Group Inc. Insiders own approximately 5.74% to 8.29% of the company's stock. William Mariner Greenman is noted as the largest individual Cerus shareholder, holding approximately 2.60% of the company's shares.